Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...
Zacks Investment Research on MSN9d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyShares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback